SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Alvegård Thor) "

Sökning: WFRF:(Alvegård Thor)

  • Resultat 1-10 av 44
  • [1]2345Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Smeland, Sigbjorn, et al. (författare)
  • Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
  • 2011
  • Ingår i: Acta orthopaedica. - 1745-3682. ; 82:2, s. 211-6
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and purpose The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from previous SSG trials and other osteosarcoma intergroup trials, and has been considered the best standard of care for patients with extremity localized, non-metastatic osteosarcoma. We analyzed the outcome in 63 consecutive patients. Patients and methods From 2001 through 2005, 63 patients recruited from centers in Sweden, Norway, and Finland were included. They received preoperative chemotherapy consisting of 2 cycles of paired methotrexate (12 g/m(2)), cisplatin (90 mg/m(2)), and doxorubicin (75 mg/m(2)). 3 cycles were administered post-operatively, and poor histological responders were given 3 additional cycles of ifosfamide (10-12 g/m(2)) as a salvage strategy. Results With a median follow-up of 77 months for survivors, the estimated metastasis-free and sarcoma-related survival at 5 years was 70% and 76%, respectively. 53 patients were treated with limb salvage surgery or rotationplasty and 2 patients experienced a local recurrence. 3 toxic deaths were recorded, all related to acute toxicity from chemotherapy. The 5-year metastasis-free survival of poor histological responders receiving add-on treatment with ifosfamide was 47%, as compared to 89% for good histological responders. Interpretation Outcome from the SSG XIV protocol compares favorably with the results of previous SSG trials and other published osteosarcoma trials. However, salvage therapy given to poor responders did not improve outcome to a similar degree as for good responders. In a multi-institutional setting, more than four-fifths of the patients were operated with limb salvage surgery or rotationplasty, with few local recurrences.
2.
  •  
3.
  • Alvegård, Thor, et al. (författare)
  • Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience
  • 1990
  • Ingår i: Journal of Clinical Oncology. - American Society of Clinical Oncology. - 1527-7755. ; 8:3, s. 538-547
  • Tidskriftsartikel (refereegranskat)abstract
    • The nuclear DNA content of 148 high-grade soft tissue sarcomas of the extremities and trunk was determined by flow cytometry, using tumor material from paraffin-embedded tissue. The patients were part of a prospective randomized clinical trial on the efficacy of adjuvant single-agent chemotherapy with doxorubicin. Chemotherapy did not improve the metastasis-free survival (MFS). After a median follow-up time of 48 months (range, 2 to 97), a multivariate analysis of prognostic factors for developing metastatic disease was performed. DNA aneuploidy was found to be an independent prognostic risk factor in addition to histologic malignancy grade IV, intratumoral vascular invasion, tumor size over 10 cm, and male sex. Patients with none or one risk factor had a 5-year MFS of 79%, with two risk factors 65%, with three risk factors 43%, and with four and five risk factors 0%. About one half (78 of 148) of the patients with three factors or less belonged to a group with a MFS over 60%. The combination of different risk factors, including DNA aneuploidy, seems to be a useful prognostic model for soft tissue sarcomas, which could be of value to select high-risk patients for further trials with adjunctive therapy.
  •  
4.
5.
6.
  • Bauer, Henrik C. F, et al. (författare)
  • Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register
  • 2001
  • Ingår i: Acta Orthopaedica Scandinavica. - Taylor & Francis. - 0001-6470. ; 72:2, s. 150-159
  • Tidskriftsartikel (refereegranskat)abstract
    • This report is based on 1.851 adult patients with soft tissue sarcoma (STS) of the extremities or trunk wall diagnosed between 1986 and 1997 and reported from all tertiary referral centers in Norway and Sweden. The median age at diagnosis was 65 years and the male-to-female ratio was 1.1:1. One third of the tumors were subcutaneous, one third deep, intramuscular and one third deep, extramuscular. The median size was 7 (1-35) cm and 75% were high grade (III-IV). Metastases at presentation were diagnosed in 8% of the patients. Two thirds of STS patients were referred before surgery and the referral practices have improved during the study. The preoperative morphologic diagnosis was made with fine-needle aspiration cytology in 81%, core-needle biopsy in 9% and incisional biopsy in 10%. The frequency of amputations has decreased from 15% in 198688 to 9% in 1995-1997. A wide surgical margin was achieved in 77% of subcutaneous and 60% of deep-seated lesions. Overall, 24% of operated STS patients had adjuvant radiotherapy. The use of such therapy at sarcoma centers increased from 20% 1986-88 to 30% in 1995-97. Follow-up has been reported in 96% of the patients. The cumulative local recurrence rate was 0.20 at 5 years and 0.24 at 10 years. The 5-year metastasis-free survival rate was 0.70.
  •  
7.
8.
9.
  • CHOONG, PETER F.M., et al. (författare)
  • Expression of proliferating cell nuclear antigen (PCNA) and Ki‐67 in soft tissue sarcoma. Is prognostic significance histotype‐specific?
  • 1995
  • Ingår i: APMIS. - John Wiley and Sons Inc.. - 0903-4641. ; 103:7-8, s. 797-805
  • Forskningsöversikt (refereegranskat)abstract
    • Abnormal patterns of proliferation characterize the behavior of many tumors. Proliferating cell nuclear antigen (PCNA) and Ki‐67 are two cell cycle antigens which are expressed in proliferative states. Our study examines the prognostic value of these cell‐cycle antigens in soft tissue sarcoma (STS). Paraffin‐embedded primary tumor tissues from 185 patients (1980–92) were stained with the anti‐PCNA antibody PC‐10; 182 of these were stained with the antibody MIB‐1 for Ki‐67. Using PCNA (≤50; >50%) and Ki‐67 (≤10; >10%) indices, we examined and compared metastasis‐free survival (MFS) in a mixed‐histotype group, as well as after subdivision into MFH and non‐MFH groups. Fifty‐seven patients developed metastases. The median follow‐up for survivors was 6 (2–13) years. In the mixed series, the 2‐year MFS for a PCNA index ≤50 was 76%, and for an index >50 56%. Survival predicted by Ki‐67 index was comparable. PCNA index (but not Ki‐67) strongly correlated with the incidence of metastasis in MFH tumors and predicted 2‐year MFS of 81 vs 48%. In contrast, Ki‐67 index (but not PCNA) strongly correlated with metastasis in non‐MFH tumors and predicted 2‐year MFS survival of 90 vs 45%. No correlation existed between PCNA and Ki‐67 indices in the mixed histotype, MFH or non‐MFH groups. In combination, a high PCNA and Ki‐67 index correlated with poor survival, a high PCNA and lower Ki‐67 index (or vice versa) with an intermediate survival, and low PCNA and Ki‐67 indices with the best survival. The pattern of PCNA and Ki‐67 expression raises the possibility of histotype specificity.
  •  
10.
  • Choong, Peter F.M., et al. (författare)
  • Urokinase-plasminogen-activator levels and prognosis in 69 soft-tissue sarcomas
  • 1996
  • Ingår i: International Journal of Cancer. - John Wiley and Sons Inc.. - 0020-7136. ; 69:4, s. 268-272
  • Tidskriftsartikel (refereegranskat)abstract
    • The local and systemic invasiveness of soft-tissue sarcomas may depend upon an interaction between the primary tumour and the extracellular matrix in which the proteolytic enzyme, urokinase plasminogen activator (uPA), may have an important role. We analyzed the expression of uPA in soft-tissue sarcoma using a luminescent immunoassay technique; and examined the relationships between different uPA levels and tumour characteristics and behaviour. We evaluated 69 adult patients with surgically treated soft-tissue sarcomas (MFH 43, leiomyosarcoma 8, liposarcoma 5, synovial sarcoma 4, others 9) of the extremities and trunk wall. Sixteen developed local recurrences, 26 developed metastases, and 5 had both. The median follow-up for survivors was 55 (30-80) months. The median uPA level was 1.4 (0.04-10.6) ng/mg protein. Increasing uPA levels correlated with increasing grade, malignant fibrous histiocytomas, leiomyosarcomas, DNA non-diploidy, tumour necrosis, local recurrence, and metastasis. Storiform-pleomorphic MFH had higher uPA levels than the myxoid variant. A cut-off value of 0.25 ng/mg protein was identified, above which local recurrence and metastasis occurred more frequently. High uPA levels appear to reflect the malignant phenotype in soft-tissue sarcoma, thus supporting the role of uPA as a prognostic indicator.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 44
  • [1]2345Nästa
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy